NEW YORK (GenomeWeb News) – Interleukin Genetics said after the close of the market on Tuesday that its revenues for the second quarter were essentially flat compared to the year-ago period.

The Waltham, Mass.-based genetic test developer said that during the three months ended June 30, it brought in revenues of $799,435, compared to $796,865 for Q2 a year ago. Genetic testing service revenue dipped slightly to $777,549 from $779,116 while other revenues increased to $21,886 from $17,749.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.